Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- MHLW to Survey, Consider Measures for Clinical Trials in Coping with Earthquakes
October 17, 2011
- Health Minister Shows Positive Attitude Towards Participation in TPP Talks
October 17, 2011
- Vice Minister Tsuji Supports Continuation of Premium for New Drug Development
October 17, 2011
- Korosho Task Force Discusses Upcoming Switch to Inactivated Polio Vaccine
October 17, 2011
- Avastin Approved for Treatment of Breast Cancer in Combination with Paclitaxel
October 13, 2011
- Revision of Ryotan-kisoku to Be Considered to Control Dispensing Point Services
October 13, 2011
- Chuikyo to Discuss “Dispensing Points” Offered by Pharmacies
October 12, 2011
- Drug Expenditure Higher than Apparent Due to Hidden Drug Expenditure: Korosho
October 12, 2011
- Headquarters for Promotion of Social Security Reform Holds 1st Meeting
October 11, 2011
- Korosho Expresses Opposition to Break-Up, Privatization of PMDA
October 11, 2011
- Decline in Research by Univ. Hospital Doctors Presents “Alarming Situation”: MEXT Official
October 10, 2011
- HPV Vaccines Competing for Public Subsidies; Are Parents Avoiding Vaccination by OB/GYN Doctors?
October 10, 2011
- Korosho Asks Committee to Discuss Re-pricing of Combination Drugs with Long-listed APIs
October 10, 2011
- Chuikyo to Focus on NHI Price Reduction for Long-listed Drugs: Dr Adachi
October 10, 2011
- PFSB’s Safety Division Calls For Revision of Tegretol Package Insert
October 10, 2011
- Korosho Announces Revision of Precautions in Prazaxa Package Insert
October 10, 2011
- MHLW to Set Up New System to Support Ultra-Orphan Drug Development
October 7, 2011
- Number of Pharmacies Qualifying for Premiums for GE Drug Dispensing Systems Down in 2010
October 6, 2011
- MHLW Issues GL for Clinical Evaluation for Renal Anemia Drugs
October 5, 2011
- PMDA Invites Opinions on Candidate Drugs for JP Listing
October 5, 2011
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…